Stay updated on Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial page.

Latest updates to the Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial page
- ChecktodayChange DetectedA new publication citation by Leighl NB et al. was added to the Publications section. The citation describes a plain-language summary of subcutaneous versus intravenous amivantamab plus lazertinib in EGFR-mutated NSCLC and notes that it is online ahead of print.SummaryDifference0.0%

- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page now shows Revision: v3.6.5, replacing the previous Revision: v3.6.4. This indicates a minor update to the page's version metadata rather than any changes to study content.SummaryDifference0.0%

- Check21 days agoChange DetectedTwo new update dates (2026-07-31 and 2026-07-30) were added and two earlier dates (2026-07-06 and 2026-07-02) were removed from the study's record history, reflecting maintenance of the listing's update chronology.SummaryDifference0.1%

- Check35 days agoChange DetectedThe page's revision number was updated from v3.6.3 to v3.6.4, signaling a small platform or content update rather than a change to study data.SummaryDifference0.0%

- Check50 days agoChange DetectedNew update timestamps (2026-07-06, 2026-07-02, 2026-07) were added and older ones (2026-06-08, 2026-06-04, 2026-06) removed in the study's record dates, reflecting the current update chronology.SummaryDifference0.1%

- Check57 days agoChange DetectedRevision label on the page changed from v3.6.0 to v3.6.3, indicating a newer version of the page. This appears to be a revision history update rather than a substantive change to the study content or user-facing information.SummaryDifference0.0%

Stay in the know with updates to Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial page.